Guest guest Posted March 24, 2006 Report Share Posted March 24, 2006 In einer eMail vom 25.03.2006 08:08:06 Westeuropäische Normalzeit schreibt jackalope_lepus@...: Avian flu is just one bug of many plagues this speaking makes it look pretty harmless. Not worse than any other plague . Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 24, 2006 Report Share Posted March 24, 2006 He ignores the need to invest in the world public health infrastructure. Avian flu is just one bug of many plagues on the way if we do nothing. There will be more global pandemics. As for American skepticism, he forgets Orson Welles " War of the Worlds " broadcast and the reaction of so many. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 25, 2006 Report Share Posted April 25, 2006 , I agree completely! ------------------- Date: Mon, 24 Apr 2006 23:05:52 -0000 From: "djberle" <dberle@...> Subject: another perspective (was...voicemail....) With all due respect to your frustration...I feel for the s. I can only imagine the position these people are placed in...with vices that grip them on all sides. I commend them for trying hard to raise the level of awareness and keep it all in check. We are trying to unfold decades of damage and deceit and evidence of harm. Decades. I thikn they are doing the best that they possibly can with the constraints around them. I expect if we keep pushing for more research and science..the truth will keep unfolding and it will become much easier for those in the limelight to speak up. A producer at Good morning America told me that 'thimerosal' is a more taboo/volatile word than abortion, lethal injection and even war. (ture story). I expect some may disagree with me but I thank the s for all they have done by taking an extremely private experience and trying to help more by exposing themselves. Could they do more? Sure. Probably. Could they have done a whole heck of alot less? Most definitely. With respect, Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 19, 2008 Report Share Posted October 19, 2008 More Targeted Cancer Therapies Set to Become " Blockbusters " Zosia Chustecka Medscape Medical News 2008. © 2008 Medscape October 10, 2008 Targeted cancer therapies, in addition to advancing the treatment of cancer, have become a growing commercial success story, and sales of these products are driving the overall growth of the oncology pharmaceutical market. At the moment, 5 such products are bringing in annual sales of more than $1 billion, and 8 more are forecast to reach this " blockbuster " status over the next few years, according to a new Datamonitor report. The 3 top-selling targeted cancer therapeutics are rituximab (Rituxan), trastuzumab (Herceptin), and bevacizumab (Avastin), and all 3 are from Roche/Genentech. The other 2 products that have sales of more than $1 billion are cetuximab (Erbitux; Bristol-Myers Squibb/ImClone) and imatinib (Gleevec; Novartis). The 8 products that have fast-growing sales and are predicted by Datamonitor to become blockbusters within the next few years are: * erlotinib (Tarceva; OSI/Genentech/Roche) * bortezomib (Velcade; Takeda/ & ) * sunitinib (Sutent; Pfizer) * lenalidomide (Revlimid; Celgene) * panitumumab (Vectibix; Amgen/Takeda) * sorafenib (Nexavar; Onyx/Bayer Schering) * lapatinib (Tykerb; GlaxoKline) * nilotinib (Tasigna; Novartis) Combined sales of targeted cancer therapies totaled $17.3 billion in 2007, and had increased by a " staggering 33% in just a year, " commented Datamonitor's oncology analyst Tom Gray, PhD. For comparison, sales for conventional chemotherapy (branded cytotoxics only) totaled $10.2 million in 2007. These figures comprise sales in 7 major markets worldwide the United States, the United Kingdom, France, Germany, Italy, Spain, and Japan. There are currently 24 targeted cancer therapeutics available in these 7 markets, and Datamonitor predicts that sales of these products will continue to increase, by around 11% each year, until they reach $42 billion or more by the year 2017. " Sales of targeted therapies have helped to drive overall growth in the cancer market because not only are they very successful and popular, they are higher priced than cytotoxics, " Dick from Datamonitor told Medscape Oncology. However, the higher price of these targeted products has created problems for their acceptance into national healthcare systems, the report notes. It cites as a prime example the United Kingdom, where the National Institute for Health and Clinical Excellence (NICE) has recommended against the use of several of the new targeted therapies on the grounds of low cost-effectiveness. The most recent example of this was in August 2008, when NICE recommended against the use of bevacizumab, sorafenib, sunitinib, and temsirolimus (Torisel; Wyeth) for the treatment of kidney cancer, eliciting protests from prominent cancer specialists, as reported at the time by Medscape Oncology . " If other healthcare systems follow the UK's example, which looks like an increasing possibility, this could significantly dampen the growth of the market, and will ultimately impact the effectiveness of treatment available to patients, " Dr. Gray commented. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.